China Biotech - Rising Stars ?

No one doubts health care in China is becoming an ever bigger story and no one will be surprised to see the Chinese authorities focus doggedly on strengthening the country’s pharmaceutical research

The small number of Chinese companies dedicated to clinical research and listed on U.S. exchanges (essentially on NASDAQ) are a poor reflection of national research occuring in the field

This is all the more reason to watch share price trends of these firms closely, as their progress will mirror governmentall policy (and financial support) to the entire sector

Dominated by BeiGene Invalid tag asset, a market cap heavyweight of $25 bn, 20.5% owned by Amgen , our short list calls for further evaluation of firms such as Gracell Biotechnologies Invalid tag asset or I-Mab , notable under-performers over the past 12 months

• High hopes in BeiGene's anti-PD-1 antibody tislelizumab, for the treatment of various solid tumor cancers is a factor in the firm's recentlly announced partnerships with Novartis - , (Februari '21), with  111.Inc. , a leading tech-enabled healthcare platform company, (March '21) and with major pharmaceuticals firm HUTCHMED (China)   (May '20), buttressing share prices and signaling an ambitious distribution strategy

Biotech company share prices are volatile because of the close correlation with experimental outcomes and no recommendation for any single company can be made

However,  the performance of our selection stands out